The makers of a twice-rejected pill designed to boost female libido are resubmitting their drug to federal health regulators, following a recent lobbying blitz by politicians, women’s groups and consumer advocates aimed at pushing it onto the market. Sprout Pharmaceuticals said Tuesday it is refiling its application for the drug, flibanserin, adding new information requested by the Food and Drug Administration about how the pill affects driving ability.

Click here to read original article